News

Sun Pharmaceutical Industries announced that CRISIL has removed the `Rating Watch with Developing Implications` status and has reaffirmed the rating assigned to the Company`s long-term bank facilities at `CRISIL AAA/Stable` (Reaffirmed; Removed from `Rating Watch with Developing Implications`).

Net profit of Sun Pharmaceutical Industries rose 27.04% to Rs 2894.79 crore in the quarter ended June 2026 as against Rs 2278.63 crore during the previous quarter ended June 2025. Sales rose 10.14% to Rs 15183.55 crore in the quarter ended June 2026 as against Rs 13786.07 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales15183.5513786.07 10 OPM %29.1031.20 - PBDT5041.624691.32 7 PBT4302.903990.77 8 NP2894.792278.63 27 Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced that the stockholders of Organon & Co. (Organon) have approved the proposals in connection with the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc., an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval marks an important milestone towards completion of the proposed transaction. The acquisition remains subject to the satisfaction of the remaining customary closing conditions, including applicable regulatory approvals.

Sun Pharmaceutical Industries has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise.Sun Pharma plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing. �South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals, said Aalok Shanghvi, Chief Operating Officer, Sun Pharma.

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 July 2026.